INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO

摘要

Among CD20-positive cancers, some develop a resistance to obinutuzumab and some reappear after being treated with the use of obinutuzumab.　According to the present invention, against a CD20-positive cancer resistant to obinutuzumab or a CD20-positive cancer reappearing after being treated with the use of obinutuzumab, a type II anti-CD20 antibody is used together with at least one compound selected from the group consisting of prednisolone, doxorubicin, vincristine, salts thereof and prodrugs thereof. Among these compounds, prednisolone, doxorubicin, salts thereof and prodrugs thereof may be selected. Among these compounds, moreover, prednisolone, salts thereof and prodrugs thereof may be selected.